Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new enzyme combo supplement targeting FODMAPs — common IBS triggers — significantly reduced symptom severity in a 4-week study of 442 patients. Nearly 70% of participants saw meaningful improvement in abdominal pain, bloating, and quality of life. Experts are encouraged but say randomized controlled trials are needed before it can be clinically recommended.
Managing irritable bowel syndrome (IBS) just got a potential new tool. A prospective study presented at the ACG 2026 Annual Scientific Meeting found that a commercially available enzyme combination supplement (Fodzyme, Kiwi Biosciences) — designed to break down three key FODMAPs (fructans, galacto-oligosaccharides, and lactose) — led to significant symptom improvements over just four weeks. The supplement is sprinkled directly into food, offering a more flexible alternative to the notoriously restrictive low-FODMAP diet.
The study enrolled 442 IBS patients, and results were consistent across IBS subtypes (constipation-predominant, diarrhea-predominant, and mixed). Notably, nearly half of participants were already following a low-FODMAP diet at baseline, suggesting the enzyme combo may offer additive benefit even for diet-adherent patients.
By the Numbers:
Why it matters: For the millions of IBS sufferers who struggle with long-term dietary restrictions, a supplement that targets dietary triggers without eliminating foods could be a meaningful addition to existing management strategies — if future placebo-controlled trials confirm these promising early signals.
